FindTrial
Sign In

J3R-MC-YDAG - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523657-34-00
Enrollment
62
Registered
2026-03-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Overweight

Brief summary

Percent Change from Baseline in Body Weight [Time Frame: Baseline, Week 64

Interventions

DRUGEloralintide
DRUGPlacebo to match LY

Sponsors

Eli Lilly & Co.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Percent Change from Baseline in Body Weight [Time Frame: Baseline, Week 64—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 28, 2026